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Abstract It has been uncertain whether specific disease-
relevant biomarker phenotypes can be found using sporadic
Parkinson’s disease (PD) patient-derived samples, as it has
been proposed that there may be a plethora of underlying
causes and pathological mechanisms. Fibroblasts derived
from familial PD patients harboring leucine-rich repeat kinase
2 (LRRK2), PTEN-induced putative kinase 1 (PINK1), and
Parkin mutations show clear disease-relevant mitochondrial
phenotypes, which are exacerbated under conditions of phar-
macological stress. We utilized fibroblasts derived from non-
familial sporadic PD patients (without LRRK2 mutations) or
LRRK2mutation carriers to directly compare the cellular phe-
notypes during and after mitochondrial stress. We then deter-
mined the effects of pharmacological LRRK2 kinase inhibi-
tion using LRRK2-in-1. We found that there were two distinct
populations of sporadic PD patient-derived fibroblast lines.
One group of sporadic PD lines was highly susceptible to
valinomycin-induced mitochondrial depolarization, emulat-
ing the mutant LRRK2 phenotype. These lines showed ele-
vated mitochondrial superoxide/ nitric oxide levels, displayed
increased mitochondrial and lysosome co-localization, and an
increased rate of mitochondrial collapse, which corresponded
with changes in mitochondrial fission and fusion proteins. The
application of LRRK2-in-1 reversed decreased levels of mito-
chondrial and lysosome co-localization and partially restored
mitochondrial network associated proteins and the mitochon-
drial membrane potential in the fibroblasts. This study iden-
tifies novel mitochondrial biomarkers in sporadic PD patient-
derived fibroblast lines, which could be used as preclinical
tools in which to test novel and known neuroprotective
compounds.
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Introduction
Sporadic Parkinson’s disease (PD) accounts for 90 % of the
global PD population [1] and there is likely to be a large
number of underlying causes [2–5]. This may pose a signifi-
cant problem in testing new treatments at clinical trial as a
Bone size fits all^ approachmay yield few significant findings.
Therefore, it is imperative to test therapeutics in easily acces-
sible tissues, such as fibroblasts, from sporadic PD patients to
determine if and how they will respond to novel treatments.
For example, there has been much debate over whether
leucine-rich repeat kinase 2 (LRRK2) kinase inhibition, using
small molecules, would be beneficial in sporadic cases [6] and
consequently, only LRRK2 mutation carriers have been re-
cruited to clinical trial. To test such therapeutics, a reliable
and robust readout of cellular function must be achieved for
the analysis of sporadic PD cases on an individual basis. We
therefore hypothesized that specific phenotypes observed
using fibroblasts, obtained by a skin biopsy, could be used
as a diagnostic tool for the ability of novel treatments to pre-
vent mitochondrial phenotypes observed in the prodromal
phase. There has been much focus on investigating prodromal
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changes in mouse models of PD [7] and finding new bio-
markers in human cell lines will inevitably broaden the tools
available for testing novel therapeutics.
Familial and sporadic PD-derived fibroblast lines show
disease-relevant changes in mitochondrial-associated gene ex-
pression profiles [8]. In addition, we and others have charac-
terized mitochondrial phenotypes in fibroblast cell lines har-
boring LRRK2 [9–14], PTEN-induced putative kinase 1
(PINK1) [8, 10, 15], and Parkin [16–20] mutations, both at
baseline and under conditions of pharmacological stress. Spe-
cifically, mutant LRRK2 carrying fibroblast lines have been
instrumental to investigate mitochondrial phenotypes and
hence, have recently been used for exploratory drug screens
[21]. The expression of the G2019S LRRK2 mutation in fi-
broblast cells was found to be associated with mitochondrial
uncoupling [13], excessive fission [14], elevated autophagy
levels [14], and mitochondrial depolarization [13]. Despite
these clear mitochondrial phenotypes, little is known about
how LRRK2 functions in this context [22]. Recently, it has
been determined that LRRK2 and the mitochondrial fission
protein dynamin-like protein 1 (DLP1) can interact in neurons
[23, 24]. Levels of DLP1 are increased in SH-SY5Y-derived
cells following the expression of mutant LRRK2 (G2019S
and R1441C) [24]. Furthermore, dominant negative DLP1
can mitigate this phenotype [14]. It is currently unknown
whether this mechanism relies on the phosphorylation state
of LRRK2 and whether currently available LRRK2 kinase
inhibitors could rescue this fission phenotype. The role of
LRRK2 in sporadic PD is poorly understood. Recently, a pro-
teomic screen has revealed critical LRRK2 interacting pro-
teins, known to affect Golgi clearance by autophagy [25].
Two of these proteins, GAK and Rab7L1, have been identified
in risk loci by GWAS-based screening of sporadic PD patients
[25]. This suggests that LRRK2-mediated pathway dysregu-
lation may link sporadic and familial PD. Sporadic PD
patient-derived fibroblast lines were recently shown to be
more vulnerably to rotenone toxicity [26]. Under this para-
digm, cells displayed deficits in the ubiquitin proteasome sys-
tem and mitochondrial respiration; however, autophagy and
redox changes could not be detected [26]. The specific bio-
logical processes controlled by LRRK2 have yet to be inves-
tigated in sporadic PD-derived fibroblast cell lines.
We have previously investigated induced pluripotent stem
cells (iPSCs) derived from dermal fibroblasts from PD pa-
tients harboring mutations in LRRK2 and PINK1 and differ-
entiated to neural cells, following treatment with specific
small molecules such as valinomycin, oligomycin, CCCP,
and rotenone that are specifically detrimental to mitochondrial
function [10]. The depolarization of mitochondria caused by
the K+ ionophore and valinomycin, caused similar responses
in familial PD patient-derived fibroblast lines and neural cells
[10], and hence, is likely the most relevant agent in which to
exacerbate phenotypes in sporadic fibroblast lines. Preventing
mitochondrial depolarization as the result of impaired clear-
ance, complex 1 inhibition, defective fission/fusion events,
calcium homeostasis deficits, and oxidative stress [27] is a
reasonable therapeutic pathway for PD.
In these experiments, we utilized fibroblasts derived from
sporadic PD patients and LRRK2mutation carriers and direct-
ly compared the phenotypes observed following mitochondri-
al stress and the beneficial effect of pharmacological LRRK2
kinase inhibition. The LRRK2-in-1 compound was chosen to
test in this system, as it is one of the few compounds that
targets both the mutant and wild-type forms of LRRK2 [28]
and hence, would be applicable for the treatment of both
LRRK2 mutation-carrying and sporadic PD patients. This
study proposes a number of cell stress biomarker phenotypes,
which could be used as preclinical diagnostic tools in which to
test novel and known compounds for their ability to amelio-
rate mitochondrial deficits.
Materials and Methods
Fibroblast Lines and Sequencing
Sporadic PD patient (N=10) and healthy subject control (N=
14)-derived fibroblast cell lines were obtained from Coriell
and the NIA Aging Cell biorepositories (ID numbers are in-
dicated in Supp. Table 1- online resource). Sporadic PD pa-
tient and healthy subject control-derived fibroblast cell lines
were age and gender matched where possible. Mutant LRRK2
(G2019S N=4 and R1441C N=4)-derived fibroblast lines
were used were either previously described [10] or obtained
from the Mayo Clinic. Sporadic PD patient-derived fibroblast
lines were obtained from patients that did not have a family
history of PD and sequencing results indicated that they did
not have mutations in LRRK2 or GBA1 genes. Sequencing
was carried out at the Harvard Medical School Translational
Genomics Core (Cambridge, MA) using Nextera PCR (for
LRRK2) and MiSeq (for GBA1) systems (Illumina).
Cell Culture
PD patient and healthy subject control-derived fibroblast lines
were cultured in standard medium containing DMEM
(Gibco), 10 % FBS (Hyclone), and 1 % Penicillin-
streptomycin (Gibco #10378-016), 0.5 % glutamine (Gibco),
and 1 % non-essential amino acids (Gibco). Cell cultures were
incubated at 37 °C and 5 % CO2. Cells were grown on 10-cm
dishes and passaged twice per week or when confluence
reached approximately 90 %. For each passage, cells were
washed in PBS and dissociated using 0.05% Trypsin (Gibco).
Cell passage numbers did not exceed 20.
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Pharmacological Compounds
For pharmacological assays, cells were incubated with
valinomycin (Sigma) in standard cell culture media with
0.1 % DMSO at range of 0.1 to 200 μM. 0.1 % DMSO was
added to the culture media for control conditions. The LRRK2
kinase inhibitor LRRK2-in-1 was co-administered with
valinomycin (10 μM) at ranges of 1–30 μM in 0.1 % DMSO.
LDH Release Assay
In vitro toxicity was determined by lactate dehydrogenase
(LDH) assay (Roche) to measure the conversion of a tetrazo-
lium substrate by LDH enzyme released through the cell plas-
ma membrane during cell death. Fibroblasts were placed in a
clear, flat-bottomed 96-well plate at a density of 5000 cells per
well. Two days post plating, cells were incubated at 37°Cwith
either valinomycin, a combination of valinomycin, and
LRRK2-in-1 or vehicle. The dose of LRRK2-in-1 was tested
to avoid drug-mediated toxicity. The substrate and catalyst
were applied according to the manufacturer’s instructions.
The LDH-based colorimetric change was analyzed according
to the manufacturer’s instructions using the Spectra Max Plus
384 spectrophotometer and Soft Max Pro 5.4.4 software. The
optical density of each line was subtracted from a lyzed con-
trol for that same line and samples were run in triplicate.
Nitric Oxide and Superoxide Analysis
Fibroblasts were plated at a density of 5000 cells per
well in 96-well plates containing for 48 h. Cells were
treated small molecules or vehicle and incubated for
24 h. DAF-FM diacetate (4-amino-5-methylamino-2′,7′-
difluorofluorescein diacetate) (Life technologies) and
MitoSOX™ Red (Life technologies) were used for the
detection of nitric oxide and superoxide, respectively.
Then, 10 μM of DAF-FM diacetate was applied to the
media containing small molecules for 1 h at 37 °C.
Cells were washed in media and left for 30 min at
37 °C to allow for complete de-esterification of the
diacetates and imaged immediately. MitoSOX™ Red
was applied to cells at a 5-μM working solution in
the media containing the small molecules. Fibroblasts
were incubated at 37 °C for 10 min, washed in media,
and imaged immediately. Six images were taken per
well using the IncuCyte ZOOM live cell imager (Essen
Bioscience) at 37 °C. The average fluorescent intensity
of DAF-FM and MitoSOX™ Red was determined for
each image using IncuCyte ZOOM software (Essen Bio-
science) and averaged for each well. Samples were run
in triplicate.
Mitochondrial Membrane Potential and Toxicity Assays
Fibroblasts were plated at a density of 20,000 cells per well in
24-well plates containing glass coverslips for 48 h. Cells were
treated with small molecules or vehicle and incubated for 24 h,
where the confluency was approximately 80 %. The HCS
Mitochondrial Health Kit (Life Technologies) was applied to
fibroblast-seeded coverslips to simultaneously measure mito-
chondrial membrane potential and cytotoxicity, using the
MitoHealth stain and Image-iT® DEAD™ Green, respective-
ly. MitoHealth stain and Image-iT® DEAD™ Green dyes
were prepared in DMSO according to the manufacturer’s in-
structions and were added to the media for 30 min. The media
was removed and cells were fixed using 4 % paraformalde-
hyde (PFA) for 15min. Cells were then washed 3× in PBS and
incubated in Hoechst (1 mg/200 mls) for 4–5 min. Cells were
washed a further 3× in PBS and coverslips were mounted onto
slides using an aqueous mountant. Confocal images were tak-
en using the Zeiss LSM 510 meta confocal microscope and
Zen software (2009).
Immunocytochemistry
Cells were fixed by removing medium and adding 4 % PFA
for 25 min, followed by three washes in PBS. For immunocy-
tochemistry, PFA-fixed fibroblast-seeded coverslips were
washed 3× in PBS and placed in 10 % normal goat serum
with 0.3 % Triton X-100 in PBS for 1 h. Coverslips were
incubated overnight at room temperature in blocking solution
with anti-Tom20 (Santa Cruz 1:100) and anti-LAMP1
(Abcam 1:100) or anti-Parkin (Abcam 1:100). Coverslips
were washed 3× in PBS and incubated with secondary anti-
bodies in PBS for 1 h: Alexa Fluor 488 (Life Technologies,
1:500) and Alexa Fluor 568 (Life Technologies, 1:500). Cov-
erslips were washed 3× in PBS and incubated in Hoechst
(1 mg/200 mls) for 4–5 min and washed a further 3× in
PBS. Coverslips were then mounted onto slides using an
aqueous mountant. Confocal images were taken using the
Zeiss LSM 510 meta confocal microscope and Zen software
(2009).
Live Cell Imaging of Mitochondria
Fibroblasts were plated at a density of 5000 cells per well in
96-well plates containing for 48 h. Cells were treated with
small molecules or vehicle and incubated for 24 h.
MitoTracker® Red FM (Life Technologies) was used to visu-
alize mitochondria over 36 h. MitoTracker® Red FM was
reconstituted in DMSO to a concentration of 1 mM and dilut-
ed in media to a final working concentration of 300 uM. Cells
were incubated at 37 °C for 30 mins and the media replaced.
The newmedia added contained either vehicle (0.1%DMSO)
or valinomycin (10 μM). Fibroblasts lines were imaged
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immediately. Three images were taken per well, every hour,
using the IncuCyte ZOOM live cell imager (Essen Biosci-
ence) at 37 °C and 20× magnification. The average phase
contrast confluency and red object confluencywas determined
for each image using IncuCyte ZOOM software (Essen Bio-
science) and averaged for each well. Phase contrast and red
object confluency was determined using user-defined masks
(Supp. Fig. 3 - online resource). The red object confluency
was normalized to the phase contrast confluency and the data
represented as relative change in normalized red object
confluency compared to 0 h.
Immunoblotting
Cells were washed in PBS, dissociated with 0.05 % trypsin,
pelleted and resuspended in standard cell culture media. Cells
were pelleted, excess media removed and snap frozen on dry
ice. Cell lysates were resuspended in ice-cold buffer contain-
ing: 300 mM sucrose in TE buffer (Bio-Rad), Phosphatase
inhibitors I and II (1:100), proteinase inhibitors (1:100) (Ther-
mo Halt proteinase inhibitor single use cocktail), EDTA, and
1 % Triton X-100. Cell lysates were sonicated with three short
pulses. A sample of the supernatant was reserved for protein
content determination (BCA Assay, Pierce) and the remaining
solution was stored at −80 °C until further use. Then, 80mg of
each prepared protein sample were loaded into the criterion
precast 4–12.5 % SDS polyacrylamide gels (Bio-Rad) and
protein samples were run using the Bio-Rad system. Proteins
were then transferred from the gel to a PVDFmembrane by an
electrical charge of 21 Vand 2.5 amps for 7 mins. Membranes
were washed 5× in Tris-buffered saline with 0.1 % Tween 20
(TBS-T) and blocked using in 5 % protein blocker (Bio-Rad)
in TBS-T. Membranes were then incubated overnight at 4 °C
with the following primary antibodies: anti-LRRK2 (Abcam
1:2000, C41-2, ab133474), anti-pLRRK2 S955 (Abcam
1:1000), anti-pLRRK2 S935 (Abcam 1:1000), anti-pLRRK2
S973 (Abcam 1:500), anti-Parkin (Abcam 1:1000), anti-
Parkin Cell Signaling (1:1000), anti-PINK1 (Abcam
1:1000), anti-OPA1 (Abcam 1:500), anti-MARCH5 (Abcam
1:1000), anti-Drp1 (Abcam 1:1000), anti-Mfn1 (Origene
1:500), anti-Mfn2 (Abcam 1:500) and anti-GAPDH
(Millipore, 1:5000). Blots were also probed using the total
OXPHOS humanWBAntibody Cocktail (Abcam 1:500). Af-
ter washing the blots 3× in TBS-T, HRP-conjugated second-
ary antibodies were then applied for 1 h at room temperature
in 5 % protein blocker (Bio-Rad) in TBS-T. The blots were
then washed 3× TBS-T, submersed into an ECL-Plus solution
(Amersham Biosciences) and exposed using ChemiDocTM
XRS with Image LabTM software. Optical density analysis
was performed with ImageJ software (Version 1.46r) and
was used to determine the relative abundance of each protein
of interest. Bands were normalized to GAPDH for that same
sample and gel. When analyzing phosphorylated LRRK2
levels , bands were normalized to levels of non-
phosphorylated LRRK2.
Quantification and Statistics
One-way ANOVA and multivariate ANOVAs with
Bonferroni. Dunnett’s post hoc tests were used to determine
differences between fibroblast genotypes and drug treatment
conditions. All analyses were conducted using GraphPad
Prism (version 5.0) (GraphPad Software, Inc). Statistical sig-
nificance was determined at the alpha level of 0.05.
Form factor analysis was used to determine the degree of
mitochondrial network connectivity and branching in fibro-
blast lines, as done previously [18, 20]. Photomicrographs of
Tom20 stained fibroblasts were taken, converted to gray scale
and binarized using ImageJ software (Version 1.46r). A con-
tour was drawn around individual fibroblasts (N=25/group)
and the binarized image was run through the form factor anal-
ysis plug-in. Form factor was defined as (Pm2)/(4πAm),
where Pm is the length of mitochondrial outline and Am is
the area of mitochondria.
Co-localization analysis was used to determine the percent-
age of mitochondria in lysosomes per cell, as a read out of
mitophagy. Raw images of Tom20 and LAMP1 stained fibro-
blasts were taken and were run through the co-localization
plug-in using ImageJ software (version 1.46r). The plug-in
required photomicrographs in two color channels and gener-
ated an 8-bit image with only the colocalized points between
the two channels. The plug then combined the three 8-bit
images (red, green, and co-localization in white) to a single
RGB image. Representative photomicrographs are indicated
in Supp. Fig. 8 - online resource. The percent area of co-
localization was measured on threshold images using the an-
alyze particles function and expressed as a percentage of the
total area of Tom20 staining.
Results
A Group of Sporadic PD Patient Derived Fibroblast Are
Vulnerable to Mitochondrial Stress
Mitochondrial dysfunction is widely recognized as a
trigger of both sporadic and familial forms of PD and
mitochondrial abnormalities are observed in post
mortem tissue from PD patients [6, 29, 30]. Mitochon-
drial dysfunction likely plays a role in the manifestation
of the disease later in life. Recapitulating the impact of
Bmitochondrial aging^ in vitro, using juvenile cells has
been challenging; however, we and others have previ-
ously shown robust phenotypes of LRRK2, PINK1, and
Parkin mutant PD patient fibroblasts when subjected to
low doses of small molecules which induce specific
5164 Mol Neurobiol (2016) 53:5161–5177
mitochondrial stress [10, 11, 18, 20]. In order to deter-
mine the unique features of individuals with sporadic
PD, we use fibroblast samples (Supp. Table 1- online
resource) as a methodological tool to determine a num-
ber of mitochondrial stress-related biomarkers, which
can be analyzed following the application of therapeu-
tics. Sporadic PD patient-derived fibroblast lines were
age and gender matched to healthy subject controls
and following sequencing analysis were confirmed to
be both LRRK2 and GBA1 mutation negative. Mito-
chondrial stress, induced by escalating doses of
valinomycin caused divergent responses to the fibroblast
vulnerability profiles observed between patients harbor-
ing LRRK2 mutations (G2019S and R1441C) and spo-
radic PD lines, when compared to healthy subject con-
trol lines, as analyzed by a lactate dehydrogenase
(LDH) colorimetric assay (Supp. Fig. 1- online re-
source). There was a significant interaction between
dose and patient source (group × dose, F20.140=13.97,
p<0.001), which was clearly attributable to the sensitive
subgroup of idiopathic PD patients, who showed signif-
icantly heightened sensitivity at all mid-range doses, but
merging with the controls and less-sensitive controls at
the highest doses. However, for a subgroup of the spo-
radic PD patients there was no statistical interaction,
resembling healthy subject controls. We therefore
grouped patient fibroblasts that were Bhighly sensitive^
or Bnormally sensitive^ for all other analyses to deter-
mine fundamental mitochondrial-related differences be-
tween these groups. There was no statistical difference
in the mean age-of-onset (T2,8=0.08, p=n.s.) and age-
of-biospy (T2,8=0.03, p=n.s.) between highly sensitive
and normally sensitive sporadic PD groups. Groups
were also matched for gender (highly sensitive=2 F
and 3 M; normally sensitive=2 F and 3 M). Specifical-
ly, highly sensitive sporadic PD lines showed a height-
ened toxicity to valinomycin treatment at doses of
20 μM (p<0.001), 40 μM (p<0.01), and 50 μM
(p<0.05) compared to healthy subject controls, which
was equivalent to the mutant LRRK2 (G2019S) cell
death profile (Supp. Fig. 1- online resource).
Using live cell imaging, we also determined the rate
of mitochondrial collapse around the perinuclear cellular
compartment, induced by 10 μM of valinomycin over
36 h (Supp. Fig. 2a - online resource), using user-
defined masks for confluency and red object area (Supp.
Fig. 3 - online resource). Mitochondrial collapse oc-
curred at a faster rate in more sensitive sporadic PD
and LRRK2 mutation (R1441C) lines (Supp. Fig. 2b -
online resource ), most evident at 12 h (p<0.001),
(Supp. Fig. 2c - online resource). An increase in nitric
oxide species was observed under vehicle conditions in
mutant LRRK2 (G2019S) (p<0.05) and highly sensitive
sporadic PD lines (p<0.01), yet levels were not exacer-
bated further by valinomycin treatment (Supp. Fig. 4a, b
- online resource). In contrast, superoxide levels did not
differ between groups under vehicle conditions and were
increased in all PD lines following valinomycin expo-
sure (p<0.05), (Supp. Fig. 4c ,d - online resource). The
increase in nitric oxide species in sporadic PD patient-
derived fibroblast lines at 10 μM of valinomycin was
positively correlated with valinomycin-induced toxicity
observed at 50 μM (p<0.05), (Supp. Fig. 4e - online
resource). No correlation was observed between
valinomycin-mediated cell death and superoxide levels
(Supp. Fig. 4f - online resource). However, superoxide
levels and nitric oxide levels in sporadic PD patient-
derived fibroblast lines were positively correlated
(p<0.05) (Supp. Fig. 4g - online resource), indicating
a sporadic PD patient fibroblast line specific increase
in reactive oxygen species.
The Effect of LRRK2-in-1 on Valinomycin-Treated
Sporadic PD Lines
LRRK2-in-1 has been shown to efficiently reduce
LRRK2 kinase activity [28, 31–34], and is being tested
in an ongoing phase 1 clinical trial for LRRK2
mutation-carrying PD patients (clinical trial number
NCT01424475; no affiliation to the authors). We show
that 30 μM of LRRK2-in-1 efficiently reduces the vul-
nerability of fibroblasts lines to the mitochondria stress-
or valinomycin (p<0.05) (Fig. 1a). LRRK2-in-1 specif-
ically reduces the exacerbated vulnerability profile of
mutant LRRK2 (p<0.05) and highly sensitive sporadic
PD patient lines (p<0.05) to valinomycin (Fig. 1a). Giv-
en these changes, we decided to quantify the effects of
LRRK2-in-1 on LRRK2 and phosphorylated (p)LRRK2,
under conditions of mitochondrial stress, which may ef-
fect mitophagy, autophagy, and fusion/fission in the spo-
radic PD fibroblasts (Fig. 1b). Mutant LRRK2
(R1441C) fibroblast lines and sporadic PD patient lines
displayed less non-phosphorylated LRRK2 protein levels
at baseline conditions (p<0.05), in comparison to
healthy subject controls (Fig. 1c). Valinomycin exposure
caused a non-cell line-dependent decrease in non-
phosphorylated LRRK2 protein levels, which was not
rescued by LRRK2-in-1 (Fig. 1c). We next validated
the action of LRRK2-in-1 on LRRK2 kinase activity
by analyzing levels of pLRRK2 species normalized to
non-phosphorylated LRRK2 protein levels. Valinomycin
caused a significant increase in the protein levels of
pS935 in mutant LRRK2 G2019S (p<0.05) and sensi-
tive sporadic PD fibroblast lines (p<0.05), which were
significantly reduced by LRRK2-in-1 treatment
(p<0.05), (Fig. 1d). Sporadic PD lines were not
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associated with LRRK2 phosphorylation at S955 follow-
ing valinomycin exposure and an increase was only ob-
served in mutant LRRK2 G2019S fibroblast lines,
(p<0.05), (Fig. 1e). Nevertheless, the administration of
LRRK2-in-1 caused a significant reduction of pS955
LRRK2 species in these lines (p<0.05), (Fig. 1e).
Valinomycin exposure also caused an increase in
pS973 LRRK2 levels in mutant LRRK2 G2019S
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(p<0.05), mutant LRRK2 R1441C (p<0.05) and sensi-
tive sporadic PD fibroblast lines (p<0.05), (Fig. 1f).
Levels of LRRK2 phosphorylation at S973 were also
decreased to baseline levels following LRRK2 kinase
inhibition in mutant LRRK2 G2019S (p<0.01), mutant
LRRK2 R1441C (p<0.05) and sensitive sporadic PD
fibroblast lines (p<0.05), (Fig. 1f).
LRRK2-in-1 Treatment Modulates Mitochondria
Dynamics and Mitochondrial Activity in Sporadic PD
Patient-Derived Fibroblast Lines
In order to determine the degree of mitochondrial net-
work connectivity and branching in PD patient-derived
fibroblast lines, we used performed factor analysis on
individual fibroblasts, as done previously for familial
PD-derived fibroblast lines [18, 20]. We determined that
under baseline conditions, the percent of sensitive spo-
radic PD patient-derived fibroblasts with a form factor
of over 0.3 was significantly higher than HS controls
(p<0.01), (Fig. 2a, b), indicating a more fragmented
mitochondrial network. In accordance, no sporadic PD
patient-derived fibroblasts displayed a factor of lower
than 0.05 in contrast to HS controls (Fig. 2a, b). Indi-
cating that the mitochondrial network was less intercon-
nected and more mitochondria were isolated. This is
likely the effect of the increased fusion activating pro-
tein levels Mfn1 (p<0.05) and OPA1 (p<0.05), working
synergistically with a decrease in the fission-activating
protein Dlp1 (p<0.05), (Supp. Fig. 5 - online resource).
Sporadic PD patients that were highly sensitive to mi-
tochondrial stress also had an increase of the mitochon-
drial fission protein MARCH5 at baseline (p<0.05),
(Supp. Fig. 5f - online resource). Upon valinomycin
exposure, fibroblasts from both LRRK2 mutation carry-
ing and sporadic PD lines displayed a significant de-
crease in form factor bins over 0.3 (G2019S=p<0.05,
R1441C=p<0.05, normally sensitive SPD=p<0.05 and
highly sensitive sporadic PD lines=p<0.01), (Fig. 2a,
b), indicating a total collapse of mitochondria around
the cell nucleus. The outer mitochondrial fusion protein
Mfn2 was selectively increased in less-sensitive sporadic
PD lines following valinomycin exposure (p<0.05), yet
was decreased in mutant LRRK2 G2019S (p<0.05) and
R1441C (p<0.05) PD patient-derived fibroblast lines
compared to healthy subject controls (Supp. Fig. 5c -
online resource). The lack of mitochondrial connectivity
and total collapse of mitochondria by valinomycin was
also associated by decreased inner mitochondrial mem-
brane fusion protein, OPA1, in all cell lines (p<0.05),
(Supp. Fig. 5d - online resource). The mitochondrial
network collapse phenotype, was partially rescued by
LRRK2 kinase inhibition in a non-cell line-dependent
manner, as indicated by the reduction of form factor
bins over 0.3 compared to valinomycin alone conditions
(Fig. 2a, b). However, form factor bins of over 0.3
remained significantly lower in PD patient-derived fibro-
blast lines compared to HS controls (p<0.01), (Fig. 2a,
b). Although OPA1 levels were increased in healthy
subject controls, mutant LRRK2 G2019S (p<0.001),
R1441C (p<0.001) and less-sensitive sporadic lines
(p<0.001), following LRRK2 kinase inhibition, levels
were not restored in more sensitive sporadic PD-
derived fibroblast lines (Supp. Fig. 5d - online re-
source). Conversely, LRRK2-in-1 treatment was able to
decrease the elevated levels of MARCH5 in all cell
lines (p<0.001), (Supp. Fig. 5f - online resource). After
confirming the mitochondrial mislocalization and chang-
es in fission and fusion dynamics in sporadic PD
patient-derived fibroblast lines, we next analyzed the
activity of the mitochondria.
In contrast to the mitochondrial mislocalization pheno-
types of sporadic PD patient-derived fibroblast lines at
baseline, mitochondria remained active, when analyzed
by a live active mitochondrial specific dye (Fig. 3a, b).
Twenty-four hours fol lowing the appl icat ion of
Fig. 1 PD patient fibroblast line vulnerability profile to the
mitochondrial stressor valinomycin can be rescued by LRRK2-in-1 and
is associated with reduced LRRK2 and phosphorylated LRRK2 protein
levels. Following the application of valinomycin (40μM) for 24-hmutant
LRRK2 (G2019S) and highly sensitive sporadic PD patient fibroblast
lines showed and increase in toxicity, as observed by an LDH release
assay, compared to healthy subject control lines (a). The co-application
of valinomycin (40 μM) and LRRK2-in-1 (10–30 μM) for 24 h reduced
toxicity in all cells lines and the preferential increase in toxicity observed
in mutant LRRK2 (G2019S) and highly sensitive sporadic PD patient
fibroblast lines (a). A schematic diagram showing how levels of
LRRK2 may modulate the PINK1/ Parkin initiated mitophagy pathway
and fission/ fusion events under conditions of valinomycin exposure (b).
LRRK2 protein levels were reduced in mutant LRRK2 (R1441C) and
sporadic PD patient fibroblast lines at baseline and were decreased further
in all lines following valinomycin (10 μM) application (c). LRRK2-in-1
(30 μM) did not alter LRRK2 protein levels compared to valinomycin
only conditions in any of the fibroblast lines (c). The level of pLRRK2
(S935) was increased in the mutant LRRK2 (R1441C) line under vehicle
conditions (d). Valinomycin exposure for 24 h caused an increase in
pLRRK2 (S935) in healthy subject control, mutant LRRK2 (R1441C)
and sensitive sporadic PD fibroblast lines (d). Increased levels of
pLRRK2 (S935) could be reversed by LRRK2-in-1 treatment (d).
pLRRK2 (S955) was only observed in mutant LRRK2 (G2019S)
fibroblast lines and protein levels were increased following valinomycin
exposure and decreased by the application of LRRK2-in-1 (e). Protein
levels of pLRRK2 (S973) were also increased by valinomycin treatment
in mutant LRRK2 (R1441C and G2019S) and sensitive sporadic PD
fibroblast lines (f). Heightened levels of pLRRK2 (S973) were reversed
to baseline levels following LRRK2-in-1 treatment (f). Graphs are
annotated as §p<0.01 compared to healthy subject controls and
*p<0.05, **p<0.01, and ***p<0.001 compared to vehicle conditions,
as analyzed by a multivariate ANOVAs with Dunnett’s post hoc tests.
Graphs are expressed at mean±SEM. N=4–14/group for LDH assay and
N=3/group for Western blot analysis
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valinomycin, the fluorescent intensity of the mitochondria
was decreased to negligible levels in all fibroblast lines
(p<0.001), (Fig. 3a, b). There was no significant differ-
ence in the f luorescent in tens i ty of the ac t ive
mitochondria dye between mutant LRRK2 (G2019S and
R1441C), sporadic groups and healthy subject controls
under vehicle conditions (Fig. 3a, b). The co-application
of valinomycin and LRRK2-in-1 partially restored the
Fig. 2 LRRK2-in-1 can restore the excessive mitochondrial network
collapse caused by valinomycin in sporadic PD patient-derived
fibroblast lines. Representation of mitochondrial networks in healthy
subject controls, sporadic PD, and mutant LRRK2 (G2019S and
R1441C) PD patient-derived fibroblast lines under vehicle conditions,
valinomycin application, or co-application of valinomycin and LRRK2-
in-1 for 24 h (a). Under vehicle conditions, both sensitive and non
sensitive sporadic PD patient fibroblast lines had a more fragmented
mitochondrial network as indicated by a higher average form factor,
where a higher percentage of cells had a form factor score of over 0.3
(b). Following the application of valinomycin mitochondrial networks in
sensitive sporadic PD-derived fibroblast lines showed an average
decrease in form factor, with a higher percentage of cells scored less
than 0.1 and more than 0.05 (b). In healthy subject control and mutant
LRRK2 (G2019S and R1441C), PD patient-derived fibroblast lines the
mitochondrial network was either collapsed or fragmented and each of the
lines showing both high and low form factor scores. These scores were
determined to be either above 0.3 or between 0.05 and 0.1 (b). LRRK2-
in-1 treatment partially restored the collapse phenotype and form factor
scores were normalized to between 0.1 and 0.3 (b). In less-sensitive
sporadic PD patient-derived fibroblast lines restoration of form factor
by LRRK2-in-1 was caused by an increase in form factor scores
ranging between 0.05 and 0.1 (b). Graphs are annotated as *p<0.05
and **p<0.01 compared to healthy subject controls, as analyzed by a
1-way ANOVAs with Dunnett’s post hoc tests. Graphs are expressed at
mean±SEM. N=4–5/group
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activity of the mitochondria (p<0.001), which was also
independent of cell line (Fig. 3a, b). The number of dead
cells was analyzed simultaneously using a nuclear dead
stain, indicating rupture of the nuclear membrane.
Valinomycin increased the number permeated nuclei in
all cell lines (p<0.001), (Fig. 3c). Dead cells were also
preferentially increased in mutant LRRK2 (G2019S)
(p< 0.05) and highly sensitive sporadic PD lines
(p<0.05), verifying results from the LDH assay. Coincid-
ing with the rescue of mitochondrial membrane potential,
LRRK2-in-1 also reduced the number of ruptured nuclear
membranes in all cell lines and the preferential increase in
Fig. 3 LRRK2-in-1 restores mitochondrial membrane potential loss
caused by valinomycin exposure. The active mitochondria dye (red)
and dead nuclear dye (green) was used as an indicator of the loss of
mitochondrial membrane potential and cell death, respectively, caused
by 24 h of valinomycin (10 μM) exposure (a). Co-treatment with
LRRK2-in-1 for the full 24 h rescued the loss of mitochondrial
membrane potential and cell death (a). There was no significant
difference in the intensity of mitochondrial membrane potential sensing
dye between fibroblast lines at baseline (b). Valinomycin exposure
reduced the intensity of the mitochondrial membrane potential sensing
dye, in all fibroblast lines, which could be partially restored by LRRK2-
in-1, (b). Under vehicle conditions, dead permeated nuclei were only
observed in mutant LRRK2 (G2019S) fibroblast lines (c). The
application of valinomycin caused an increase in the number of dead
permeated nuclei in all cell lines, yet were preferentially higher in
mutant LRRK2 (G2019S) and sensitive sporadic PD patient-derived
fibroblast lines (c). LRRK2-in-1 reduced the presence of dead
permeated nuclei in all cell lines (c). Graphs are annotated as §p<0.05
compared to healthy subject controls and *p<0.05 and ***p<0.001
compared to vehicle conditions, as analyzed by a multivariate ANOVAs
with Dunnett’s post hoc tests. Graphs are expressed at mean±SEM. N=
4–5/group. Low-magnification scale bar=200 μM and high-
magnification scale bar=50 μM
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ruptured nuclei observed in sensitive sporadic PD
(p<0.001) and mutant LRRK2 (G2019S) (p<0.05) de-
rived fibroblast lines (Fig. 3c).
Given this cell death profile and our finding that
valinomycin induces oxidative stress, we analyzed pro-
tein levels of the oxidative stress sensitive mitochondrial
complexes, which could potentially be used as a report-
able biomarker of cellular function. LRRK2 (G2019S)
mutation carrying lines had elevated levels of mitochon-
drial complexes I (p<0.05), II (p<0.05), III (p<0.05),
and V (p<0.05), compared to healthy subject control
lines, which was not exacerbated further by valinomycin
treatment (Supp. Fig. 6 - online resource). However,
treatment by LRRK2-in-1 specifically reduced protein
levels of mitochondrial complexes I (p<0.05) and III
(p<0.001) to that of healthy subject controls (Supp.
Fig. 6- online resource). In contrast, less-sensitive spo-
radic PD lines and healthy subject controls had height-
ened levels of mitochondrial complexes II (p<0.001)
and III (p<0.001) following LRRK2-in-1 treatment,
which was not observed in highly sensitive sporadic
PD patient-derived fibroblast lines (Supp. Fig. 6 - online
resource). This indicates a divergent mitochondrial com-
plex level correction pathway, initiated by kinase inhi-
bition, between familial and sporadic PD fibroblast sam-
ples (Supp. Fig. 6 - online resource).
LRRK2-in-1 Treatment Regulates PINK1 and Parkin,
and Mitochondrial and Lysosome Co-localization in PD
Patient-Derived Fibroblast Lines
PINK1 and Parkin initiate the mitophagy pathway for
the removal of damaged mitochondria [35, 36]. We
show that deficits in mitochondrial and lysosome co-
localization, indicative of altered mitophagy, and chang-
es in the expression of PINK1 and Parkin can be de-
tected in sporadic PD patient fibroblast lines. We further
show that LRRK2-in-1 regulates levels of mitochondrial
and lysosome co-localization. A deficit in mitophagy is
an important reportable phenotype to measure in PD
patient samples as increased lysosomal activity has been
implicated in the neurite shortening phenotype of iPSC-
derived dopamine neurons harboring mutant LRRK2
(G2019S) [14]. Full-length PINK1 protein levels were
decreased G2019S and sporadic PD patient-derived fi-
broblasts lines following valinomycin exposure
(p<0.05), which was not rescued by the application of
LRRK2-in-1 (Fig. 4a). The full-length form of PINK1 is
proteolytically processed and cleaved upon entry into
mitochondria, in a voltage-dependent manner. The levels
of cleaved PINK1 did not change, in any lines, follow-
ing valinomycin exposure, yet were significantly in-
creased in mutant LRRK2 G2019S fibroblasts in all
treatment conditions, p<0.05, (Supp. Fig. 7a - online
resource). Parkin protein levels were elevated in sporad-
ic PD patient-derived fibroblast lines that were highly
sensitive to mitochondrial stress (p<0.05) and LRRK2
(G2019S) mutation carrying lines (p<0.05) at baseline
(Fig. 4b). The application of valinomycin reduced
heightened levels to that of healthy subject control lines
(p<0.05) and the co-application of LRRK2-in-1 had not
further effect (Fig. 4b). This finding was also verified
using a second Parkin antibody recognizing a different
epitope of the protein (Supp. Fig. 7b - online resource).
Parkin is distributed evenly throughout the cytoplasm
under baseline conditions and following valinomycin
treatment (Fig. 4c). However, the co-administration of
valinomycin and LRRK2-in-1 causes Parkin to be se-
questered into structures we have termed BParkin rings^
(Fig. 4c). Parkin rings were partially colocalized to mi-
tochondria (Fig. 4c). The application of LRRK2-in-1
alone does not cause the formation of Parkin rings, in-
dicating mitochondria must first be under conditions of
stress (Supp. Fig. 8b - online resource). The fluorescent
intensity of the Parkin staining did not differ between
fibroblast lines at baseline and did not increase with
valinomycin treatment (Fig. 4d). Conversely, the fluores-
cent intensity of Parkin was increased by the co-
administration of valinomycin and LRRK2-in-1 in all
cell lines (p<0.001), (Fig. 4d). This is directly related
to the accumulation of Parkin, as the number of cells
that contain Parkin rings was also increased following
the co-administration of valinomycin and LRRK2-in-1
(p<0.001), (Fig. 4e). PD patient-derived fibroblast lines
harboring a LRRK2 mutation (G2019S) had significant-
ly more Parkin rings (p<0.05), compared to healthy
subject controls and the other PD patient-derived fibro-
blast lines (Fig. 4e).
Given the changes in PINK1 and Parkin, we next
measured the degree of mitophagy in fibroblast cell
lines, which can be measured by the co-fluorescent
staining of mitochondria using Tom20 and lysosomes
using LAMP1. This was determined using a defined
co-localization algorithm, which masks and calculates
the percentage of overlap between Tom20 and LAMP1
stained areas in comparison to the total Tom20 stained
area (Supp. Fig. 9). At baseline and following
valinomycin treatment, all cell lines displayed a single
lysosome structure in the perinuclear compartment
(Fig. 5a). Accordingly, the fluorescent intensity of the
lysosome staining was not significantly different be-
tween vehicle and valinomycin-treated fibroblast lines
(Fig. 5b). The co-administration of valinomycin and
LRRK2-in-1 caused an increase in the number and size
of LAMP1-positive vesicles, which were present
throughout the cytoplasm (Fig. 5a). Consequently, the
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fluorescent intensity of LAMP1-positive lysosomes, af-
ter co-treatment was increased twofold in all cell lines
(p<0.001), (Fig. 5b). Despite the comparable LAMP1
changes of healthy subject control and PD patient-
derived fibroblasts, mitophagy levels were differently
altered (Fig. 5c). At baseline, there was more co-
localization of mitochondria and lysosomes in mutant
LRRK2 G2019S (p<0.05) and R1441C (p<0.05) and
highly sensitive sporadic PD (p<0.05) compared to both
healthy subject controls and less-sensitive sporadic PD
fibroblast lines (Fig. 5c). Mitochondrial co-localization
to the lysosome was also confined to the perinuclear
compartment in all cell lines under vehicle conditions
(Fig. 5a). Tom20 and LAMP1 co-localization was not
observed in any cell lines following valinomycin treat-
ment (Fig. 5a, c), indicating a severe defect in the re-
moval of damaged mitochondria. The co-localization of
Tom20 and LAMP1 was restored to baseline levels fol-
lowing the co-application of valinomycin and LRRK2-
in-1 in mutant LRRK2 G2019S (p<0.001) and R1441C
(p<0.001) PD and highly sensitive sporadic PD lines
(p<0.001), (Fig. 5a, c). In contrast, mitophagy levels
were above baseline levels in less-sensitive sporadic
PD lines (p<0.001) and healthy subject controls
(p<0.001) with the addition of LRRK2-in-1 (Fig. 5a,
c). The regulation of mitophagy by LRRK2-in-1 also
indicates another potential therapeutic benefit of this
compound administration. Despite the increase of lyso-
some size and number with the application of LRRK2-
in-1 alone, the co-localization of Tom20 and LAMP1
was not increased above baseline levels (Supp. Fig. 8a
- online resource). This indicates that the presence of
damaged mitochondria is required for increased
mitophagy, and not simply aberrant lysosome formation.
Discussion
Sporadic PD Patient-Derived Fibroblast Biomarkers
It is an important goal to determine reportable biomarker phe-
notypes for use as preclinical diagnostic tools for sporadic PD.
Fibroblasts have previously been characterized in cases of
familial PD, and we and others have determined robust mito-
chondrial phenotypes from lines harboring LRRK2 [9–13],
PINK1 [10, 15], and Parkin [16–20] mutations, both at base-
line and under conditions of pharmacological stress. There-
fore, in this series of experiments, we have investigated
whether sporadic (non-familial) PD patient-derived fibroblast
lines also show mitochondrial phenotypes and compare them
against lines derived from LRRK2 mutation (G2019S and
R1441C) carrying PD patients. In general, we find that
mitochondrial-associated phenotypes are greater in fibroblasts
harboring a G2019S mutation in comparison to those carrying
an R1441C mutation. This is in keeping with the fact that
LRRK2 kinase activity is preferentially increased by the
G2019S mutation, compared to other mutant forms [37, 38].
We further show that phosphorylation at S955 was exclusivity
detected in fibroblast lines carrying the G2019S mutation and
may therefore this site may be of importance to the increased
kinase activity observed in previous studies.
A key finding from our data sets show that sporadic lines
can be divided into two statistically distinct groups based on
phenotypic analysis of a number of reportable assays. Approx-
imately 50 % of the sporadic PD patient lines tested lacked
significant phenotypes when stressed using the mitochondrial
specific toxin valinomycin, yet the remaining sporadic PD
patient-derived cell lines were highly sensitive to mitochon-
drial stress. Sensitive sporadic PD-derived fibroblast lines had
comparable mitochondrial phenotypes to LRRK2 mutation
carrying lines. Although a sub-classification of sporadic cells
lines has not previously been attempted, this may have poten-
tial importance for recruiting patients for clinical trial, as not
all sporadic PD cases may respond the same way to novel
treatments. Secondly, these samples provide an accessible
pharmacodynamic system for testing individual drugs.
Specifically, we determined that sporadic PD patient-
derived fibroblast derived fibroblast lines that displayed a
more fragmented mitochondrial network, increased levels of
nitric oxide, elevated PINK1/Parkin levels, and heightened
mitophagy at baseline; were also highly sensitive to
valinomycin toxicity. These findings represent the first in-
stance where a detectable increase in mitophagy was observed
in sporadic PD patient samples and hence treatments that reg-
ulate mitochondrial turnover may represent a unified thera-
peutic approach for PD. It has been reported that mutant
LRRK2 (R1441C and G2019S) expression can induce
mitophagy in vitro, causing the removal of mitochondria in
neurons, resulting in dendrite and neurite shortening [14, 39,
40]. We now show increased mitochondria and lysosome co-
localization, implying heightened mitophagy, can also be ob-
served in human fibroblasts lines harboring LRRK2 muta-
tions, at baseline, emphasizing the use of skin biopsy-
derived fibroblasts as a candidate tool to determine biomarker
phenotypes for neuronal dysfunction. Moreover, it is possible
that aberrant mitophagy in a cohort of sporadic PD patients
may be related to early dopamine neuron terminal loss in the
disease. These data also suggest that mitochondria and lyso-
some co-localization, in sporadic PD and mutant LRRK2 mu-
tation carriers is likely to be the downstream consequence of
increased Parkin protein levels. Elevated Parkin levels have
previously been observed in sporadic PD fibroblast cells and
this was correlated with increased protein ubiquitination [26].
Despite the fact that mitochondria and lysosome co-
localization was increased at baseline in sporadic PD and mu-
tant LRRK2 fibroblast lines, this is reduced to negligible
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levels following a 24-h exposure of valinomycin at 10 μM.
We suggest that this was caused by the lack of Parkin translo-
cation to the mitochondria, which is thought to be prerequisite
to mitophagy [36]. In contrast, Parkin relocalization to the
mitochondria was previously observed following the admin-
istration valinomycin at a 1-μM concentration, at 12-h post
exposure [19]. Therefore, this phenomenon is likely time de-
pendent and may not occur with prolonged mitochondrial
stress.
A significant loss of Parkin and FL PINK1 protein levels
was observed in sensitive sporadic PD fibroblast lines and
those carrying a G2019S LRRK2 mutation following
valinomycin exposure for 24 h. It has previously been deter-
mined that Parkin levels are decreased upon valinomycin ex-
posure in non-PD cell types [19]; however, this was not ac-
companied by a loss of PINK1 [19]. We therefore suggest that
sensitive sporadic PD fibroblast lines and those carrying a
G2019S mutation may therefore have alteration in the pro-
cessing of FL PINK1 at later time points with sustained mito-
chondrial stress.
Although the majority of cellular sporadic PD phenotypes
recapitulated those of LRRK2 mutation carrying lines, the
mitochondrial fission protein Dlp1 was increased in LRRK2
mutation carrying lines, yet decreased in sporadic PD lines.
This may have implications for the newly developed discov-
ery approaches aimed to knock down Dlp1 for use in PD [41].
Based on our observations we suggest that Dlp1 knockdown
would be most suited to mutant LRRK2 (R1441C and
G2019S) carrying PD patients. Conversely, the loss of Dlp1
was recently found to cause the abnormal movement of mito-
chondria and the degradation of dopamine neurons [42];
therefore, it is also possible that loss of Dlp1 may be a bio-
marker for neuronal demise.
Following the application of valinomycin, highly sensitive
sporadic PD patient-derived fibroblast lines displayed an in-
creased collapse phenotype of mitochondria around the nucle-
us, which occurred at a faster rate than in healthy subject
control cells. We have found that this cellular phenotype is
directly relevant to dopamine neurons, in vivo, as mitochon-
drial collapse is seen in the remaining dopamine neurons in
post mortem tissue samples [29]. We suggest that this pheno-
type was caused by the increase in the mitochondrial fusions
proteins Opa1 andMfn2 and/ or the decrease in the mitochon-
drial fission protein Dlp1. These changes likely contribute to
mitochondrial collapse to the perinuclear compartment during
mitochondrial stress. Conversely, the loss of Opa1 and in-
crease of Dlp1 has also been found in other in mutant Parkin
PD patient-derived fibroblast lines [43] and this may represent
mitochondrial fragmentation, which occurs before total mito-
chondrial collapse. The sensitive group of sporadic PD lines
displayed heightened superoxide levels, loss of mitochondrial
membrane potential, a cessation of mitochondria and lyso-
some co-localization and ultimately a preferential increase in
toxicity. These phenotypes recapitulated the mutant LRRK2
cellar phenotypes.
We propose that the divergent phenotypic responses ob-
served between groups of sporadic PD patient samples may
be useful in preclinical diagnostics, where it may be possible
to discern patients that respond to novel therapeutics and those
who do not. In contrast to the valinomycin application, spo-
radic PD patient fibroblast samples treated with the complex I
inhibitor rotenone showed a decreased mitochondrial respira-
tion but did not display changes in autophagy or levels of
reactive oxygen species [26]. It may therefore be possible to
distinguish pathogenic mechanisms in sporadic PD using dif-
ferent pharmacological stressors.
Sporadic PD Patient-Derived Fibroblast Lines Respond
to LRRK2 Kinase Inhibition
It is currently unknown whether LRRK2 kinase inhibi-
tion, using small molecules, would be beneficial in spo-
radic PD cases. Since we have defined specific pheno-
types in fibroblasts derived from sporadic PD patients,
we therefore explored whether the inhibition of LRRK2
kinase activity, a current potential therapeutic interven-
tion, would reduce the phenotypes observed in sporadic
PD patient-derived fibroblast lines. These assays could
also be used as an initial screening process for selecting
sporadic PD patients for clinical trials.
Fig. 4 LRRK2-in-1 reduces PINK1 and Parkin levels in sporadic PD
patient fibroblasts and is associated with the sequestering of Parkin into
ring formations. PINK1 protein levels were significantly increased in
mutant LRRK2 (G2019S) PD patient-derived fibroblast lines with
vehicle treatment compared to valinomycin treatment, given for 24 h
(a). PINK1 protein levels were also increased in sensitive sporadic PD
patient-derived fibroblast lines with vehicle treatment compared to
LRRK2-in-1 treatment (a). The protein levels of Parkin were
significantly elevated under vehicle conditions in mutant LRRK2
(G2019S) and sensitive sporadic PD patient-derived fibroblast lines,
compared to both valinomycin treatment alone and valinomycin and
LRRK2-in-1 co-treatment (b). The location of Parkin (red) was found
to be evenly distributed throughout the cytoplasm of fibroblast lines
under vehicle and valinomycin treatment conditions, yet was
sequestered in to rings with LRRK2-in-1 and valinomycin co-treatment
(c). The mean intensity of Parkin did not differ between vehicle and
valinomycin treatment, yet was increased following valinomycin and
LRRK2-in-1 co-treatment in all fibroblast cell lines (d). There were
negligible levels of Parkin rings present in fibroblast lines under both
vehicle and valinomycin conditions (a, e). Following the application of
LRRK2-in-1, the number of cells with Parkin rings was significantly
increased in all fibroblast lines and were preferentially increased in
mutant LRRK2 (G2019S) and sporadic PD patient-derived fibroblast
lines (a, e). Parkin rings were partially colocalized with the
mitochondria (a). Graphs are annotated as §p<0.05 compared to healthy
subject controls and *p<0.05, **p<0.05, and ***p<0.001 compared to
vehicle conditions, as analyzed by a multivariate ANOVAs with
Dunnett’s post hoc tests. Graphs are expressed at mean±SEM. N=3–5/
group. Low-magnification scale bar=200 μM and high-magnification
scale bar=50 μM
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Elevated levels of pathogenic pLRRK2 (S935) and (S973)
species were increased in sensitive sporadic PD patient-
derived fibroblast lines under conditions of mitochondrial
stress. Application of LRRK2-in-1 also decreased pLRRK2
levels to baseline and further rescued the loss of mitochondrial
membrane potential. These data suggest that LRRK2-in-1
treatment may therefore be of value in a subgroup of sporadic
PD patients in addition to LRRK2 mutation carriers.
Our findings indicate that the concentration of LRRK2-in-1
required for efficient rescue of mitochondrial-related changes
in human dermal fibroblasts is higher than used to mediate
changes other neuronal cell types. A dose of 0.5 μMwas used
Fig. 5 LRRK2-in-1 induces mitochondrial localization to the lysosome
that is preferentially increased in mutant LRRK2 and a subpopulation of
sporadic PD patient-derived fibroblast lines. Under vehicle and
valinomycin conditions the subcellular localization of LAMP1-positive
lysosomes (red) in fibroblasts lines is confined to the perinuclear
compartment (a). Under vehicle conditions, a small number of Tom20-
positive mitochondria (green) could be observed in the lysosome in all
cell lines, yet the application of valinomycin for 24 h prevented LAMP1
and Tom20 co-localization (a). LRRK2-in-1 and valinomycin co-
treatment for 24 h caused an increase in lysosome formation throughout
the cytoplasm and LAMP1-positive vesicles and Tom20-positive
mitochondria were partially colocalized (a). The intensity of LAMP1
was increased in all fibroblast lines following the co-application of
valinomycin and LRRK2-in-1 (b). The percent of mitochondria in the
lysosome, under vehicle conditions, was highest in mutant LRRK2
(G2019S) and highly sensitive sporadic PD patient-derived fibroblast
lines (c). The percent co-localization of mitochondria and lysosomes
was decreased to negligible levels in all lines following valinomycin
exposure (c). Co-application of valinomycin and LRRK2-in-1 caused a
restoration of mitochondria and lysosome co-localization in mutant
LRRK2 (G2019S and R1441C) and highly sensitive PD patient-derived
fibroblast cell lines, which were comparable to levels observed at baseline
(c). In less-sensitive sporadic PD patient and healthy subject control-
derived fibroblast lines, mitochondria and lysosome co-localization was
increased above baseline levels following LRRK2-in-1 treatment (c).
Graphs are annotated as §p<0.05 compared to healthy subject controls
and ***p<0.001 compared to vehicle conditions, as analyzed by a
multivariate ANOVAs with Dunnett’s post hoc tests. Graphs are
expressed at mean±SEM. N=4–5/group. Low-magnification scale
bar=200 μM and high-magnification scale bar=50 μM
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to attenuate the toxicity caused by mutant LRRK2 transfected
SH-SY5Y cells [32], whereas a dose of 3 μM was required for
efficient LRRK2 kinase inhibition in transfected HEK293 cells
[44]. In contrast, a dose of 5 μM was needed for application to
primary cortical neurons [45]. Therefore, dose-response curves
are critically important to determine the minimal dose required
for each experimental paradigm to avoid potential Boff target^
effects. Although there are multiple kinase inhibitors available
that target mutant forms of LRRK2, the search for new potent
WT LRRK2 kinase inhibitors is much needed for future studies
investigating LRRK2 phosphorylation in sporadic PD. The re-
cently developed LRRK2 kinase inhibitor 3-[4-(morpholin-4-
yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-
06447475) holds promise for the treatment of sporadic PD since
it has a high affinity to targetWTLRRK2 and has been validated
for use in vivo [46].
LRRK2-in-1 was previously found to enhance the conver-
sion LC3 I to LC3 II which is required for the formation of the
autophagosome [34]. Mitophagy levels, as inferred by mito-
chondrial and lysosome co-localization, were also restored to
baseline levels, following LRRK2 kinase inhibition, in LRRK2
mutation carrying and sensitive sporadic lines. Conversely, the
level of mitochondrial and lysosome co-localization was in-
creased above baseline levels in healthy subject controls and
less valinomycin sensitive sporadic lines. These data support
the notion that mitophagy could be potentially used as a bio-
marker in fibroblasts. It is also reasonable that other organelles
such as the endoplasmic reticulum and peroxisomes may also
be degraded by macroautophagy in fibroblasts derived from
PD patients. Hence, it is possible other disease-relevant bio-
markers may be found in future experiments.
We find that restoration or increased mitochondrial and lyso-
some co-localization was not dependent on increased levels of
PINK1 and Parkin but rather concurrent with the formation of
Parkin into circular aggregated structures, which we have termed
BParkin rings,^ that partially co-localize with mitochondria. Al-
though the formation of these structures has not previously been
identified, it is likely that their formation is a direct consequence
of LRRK2 kinase inhibition. LRRK2 functionally interacts with
the C-terminal R2 RING finger domain of Parkin and Parkin
interacts with the COR domain of LRRK2 [47]. Further, the over
expression of Parkin is protective against mutant LRRK2
(G2019S) mediated degeneration [48]. We therefore note the
accumulation of Parkin rings in close proximity to mitochondria,
under conditions of LRRK2 kinase inhibition, is a means of
locally increasing Parkin for the stimulation of mitophagy, or
may not play a direct role. The aggregation of Parkin has previ-
ously been reported in healthy subject control iPSC-derived neu-
rons but not PINK1 mutant lines following the application of
valinomycin [49]. Unlike Parkin ring formation, the aggregation
pattern previously found was present throughout the soma and
this was correlated with the absence of mitophagy [49]. There-
fore the sequestering of Parkin may have dual roles in both the
inhibition and stimulation of mitophagy, dependent on the cellu-
lar stress phenotype.
Summary
A group of sporadic PD patient’s fibroblasts showed specific
mitochondrial phenotypes at baseline and when stressed,
equivalent to mutant LRRK2 mutation carrying PD patients.
We suggest that these defined PD-associated phenotypes can
be used as a biomarker for mitochondrial dysfunction based
on a number of reportable assays. We further conclude that
sporadic PD patient fibroblasts respond to LRRK2 kinase in-
hibition and treatment with such a compound was able to
rescue mitochondrial membrane potential and restore/ in-
crease mitochondrial and lysosome co-localization. This fi-
broblast phenotype biomarker screen suggests that some spo-
radic PD patients may be suitable candidates for LRRK2 ki-
nase inhibition treatment in clinical trials. It will also be im-
portant in future experiments to test whether PD-related mito-
chondrial phenotypes observed in fibroblasts are also seen in
cells that can be isolated from a blood sample. This would
enable a faster screening procedure that could potentially be
more easily utilized in the clinic. It was also recently shown
that familial PD-derived fibroblast lines can be used for large
scale drug screens to identify novel compounds [21] and we
suggest sporadic fibroblast lines may also be suitable candi-
dates for such screens.
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